CG Oncology (NASDAQ:CGON) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CG Oncology (NASDAQ:CGON) from a sell rating to a hold rating in a research note issued to investors on Saturday.

CGON has been the subject of a number of other reports. HC Wainwright increased their price target on CG Oncology from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Piper Sandler increased their price target on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Royal Bank Of Canada increased their price target on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 price target on shares of CG Oncology in a report on Monday, January 12th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CG Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $67.70 on Friday. The business has a fifty day moving average of $60.91 and a two-hundred day moving average of $49.77. The stock has a market cap of $5.72 billion, a P/E ratio of -32.71 and a beta of 0.70. CG Oncology has a 52-week low of $19.47 and a 52-week high of $71.90.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million during the quarter. On average, equities analysts anticipate that CG Oncology will post -1.31 earnings per share for the current year.

Insider Buying and Selling

In related news, Director James Mulay sold 1,964 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Investors Weigh In On CG Oncology

Hedge funds have recently bought and sold shares of the stock. Candriam S.C.A. raised its position in CG Oncology by 35.9% in the 3rd quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock valued at $41,806,000 after purchasing an additional 274,312 shares in the last quarter. JPMorgan Chase & Co. raised its position in CG Oncology by 321.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock valued at $9,179,000 after purchasing an additional 173,785 shares in the last quarter. Vanguard Group Inc. raised its position in CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after purchasing an additional 670,770 shares in the last quarter. Voya Investment Management LLC raised its position in CG Oncology by 217.6% in the 3rd quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock valued at $1,933,000 after purchasing an additional 32,877 shares in the last quarter. Finally, Mangrove Partners IM LLC raised its position in CG Oncology by 21.0% in the 3rd quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after purchasing an additional 116,575 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.